NCT02207374 - A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

601

Participants

Timeline

Start Date

August 4, 2014

Primary Completion Date

February 27, 2016

Study Completion Date

February 27, 2016

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

semaglutide

Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.

DRUG

DPP-4 inhibitor

Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.

Trial Locations (43)

010 8543

Novo Nordisk Investigational Site, Akita-shi, Akita

379 0116

Novo Nordisk Investigational Site, Annaka-shi, Gunma

070 0002

Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido

078 8510

Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido

113 8431

Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo

103-0027

Novo Nordisk Investigational Site, Chuo-ku Tokyo

104-0031

Novo Nordisk Investigational Site, Chuo-ku Tokyo

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

103 0027

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

104-0061

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

812 0025

Novo Nordisk Investigational Site, Fukuoka

Unknown

Novo Nordisk Investigational Site, Higashiosaka-shi, Osaka

Novo Nordisk Investigational Site, Mito-shi, Ibaraki

Novo Nordisk Investigational Site, Ota-ku, Tokyo

Novo Nordisk Investigational Site, Ube-shi, Yamaguchi

598 0048

Novo Nordisk Investigational Site, Izumisano

582 0005

Novo Nordisk Investigational Site, Kashiwara-shi, Osaka

125 0054

Novo Nordisk Investigational Site, Katsushika-ku, Tokyo

800 0252

Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka

963 8851

Novo Nordisk Investigational Site, Koriyama-shi, Fukushima

862 0976

Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto

615 8125

Novo Nordisk Investigational Site, Kyoto-shi, Kyoto

880 0034

Novo Nordisk Investigational Site, Miyazaki

311 0113

Novo Nordisk Investigational Site, Naka-shi, Ibaraki

662 0971

Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo

663-8501

Novo Nordisk Investigational Site, Nishinomiya-shi, Hyogo

831 0016

Novo Nordisk Investigational Site, Okawa-shi, Fukuoka

700 8505

Novo Nordisk Investigational Site, Okayama-shi, Okayama

532 0003

Novo Nordisk Investigational Site, Osaka-shi, Osaka

144 0035

Novo Nordisk Investigational Site, Ota-ku, Tokyo

323 0022

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

849 0937

Novo Nordisk Investigational Site, Saga-shi,Saga

060 0062

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

062 0007

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

980 0021

Novo Nordisk Investigational Site, Sendai

329 0433

Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi

160-0008

Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo

424 0853

Novo Nordisk Investigational Site, Shizuoka

565-0853

Novo Nordisk Investigational Site, Suita-shi, Osaka

569 1096

Novo Nordisk Investigational Site, Takatsuki-shi, Osaka

103-0028

Novo Nordisk Investigational Site, Tokyo

123-0845

Novo Nordisk Investigational Site, Tokyo

235 0045

Novo Nordisk Investigational Site, Yokohama